Funding
Rhythm expands LG Chem obesity drug license to $855M, secures $750M term loan
Key Facts
Signal Type
Funding
Industry
Biotech
Companies
Rhythm Pharmaceuticals, LG Chem, KKR HealthCare Royalty, Blackstone, William Blair
Date
Rhythm Pharmaceuticals and LG Chem revised their licensing agreement for the oral obesity drug bivamelagon, increasing the milestone-based deal from $305 million to $855 million. Under the new terms, Rhythm will pay $350 million in additional payments—$70 million this month, $100 million in September 2027, $100 million in September 2028, and $80 million in September 2029—while lowering royalties to 1% starting in 2029 or upon first commercial sale.
To finance the expanded deal, ongoing commercialization, and R&D, Rhythm entered a $750 million term loan facility with KKR HealthCare Royalty and Blackstone, with $500 million committed. The financing and deal terms reflect strong confidence in the MC4R franchise's multibillion-dollar potential, according to William Blair analyst Alethia Young.
Rhythm Pharmaceuticals gains expanded rights and lower long-term costs for a promising oral obesity drug, while LG Chem benefits from increased upfront payments and a potential $200 million payout if sales reach $3 billion. Clinical trial vendors and commercialization service providers should take note: Rhythm's approved injectable Imcivree grew sales 29% to $92.1 million in Q3, and the company is preparing for a Phase 3 pivotal trial of bivamelagon by year-end.
Rhythm plans to begin a Phase 3 pivotal trial of bivamelagon in hypothalamic obesity by the end of this year, with a study in Prader-Willi syndrome slated for 2027. Monitor Imcivree's sales trajectory and any additional financing or partnership moves as Rhythm executes on its pipeline and expands its commercial footprint.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
